A research team working at MedUni Vienna has demonstrated that a specific component of the immune system (PTX-3) remains at significantly higher levels in the blood of patients who have suffered from severe COVID-19, even months after the acute infection has subsided. This study identifies PTX-3 as a potential biomarker for existing tissue damage, long-term immune activation and also for complications following COVID-19.
This article was originally published on MedicalXpress.com